Background The GetGoal-L-Asia and -S trials were multi-center trials conducted in 4 and 16 countries, respectively including Japan that evaluated the efficacy and safety of lixisenatide add-on treatment vs. populace of Japanese type 2 diabetes patients included 143 patients (mean age: 59.0?years; 35?% female) treated with lixisenatide and 136 patients treated with placebo (mean age: 57.8?years; 32?% female). Among the subgroups, lixisenatide treatment vs. placebo was associated with greater change in HbA1c (Low HbA1c ?0.80?%, p?Rabbit Polyclonal to CDC7 treated with placebo and lixisenatide, respectively. Lixisenatide treated individuals got higher shifts in HbA1c ( significantly?1.08?%, self-confidence period (CI) ?1.29, ?0.86, p?Phenacetin manufacture for Japanese type 2 diabetes individuals with low (<8?%) and high (8?%) baseline HbA1c amounts Lixisenatide treated individuals Phenacetin manufacture with high (8?%) baseline HbA1c got significantly higher adjustments in HbA1c (?1.19?%, CI ?1.46, ?0.92, p?